Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Van Vloten

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
PDA Journal of Pharmaceutical Science and Technology|January 18, 2026
Reproducible and Efficient Phenotyping for Cell Therapy Manufacturing Using the Accellix Automated Flow Cytometer PlatformJacob Van Vloten, Seungmi Yoo, Gurleen Sandhu, et al.
Research Square|December 4, 2023
Chimerization of the Anti-Viral CD8<sup>+</sup> T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapyRichard Vile, Mason Webb, Jacob van Vloten, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2025
The progressively exhausted T cell response to a poorly immunogenic model of HCC can be partially rescued by immune checkpoint blockade and is heavily suppressed by T cell responses to oncolytic virotherapyThanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, et al.
Nature Communications|June 27, 2024
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell responseMason J Webb, Thanich Sangsuwannukul, Jacob van Vloten, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
PDA Journal of Pharmaceutical Science and Technology|January 18, 2026
Reproducible and Efficient Phenotyping for Cell Therapy Manufacturing Using the Accellix Automated Flow Cytometer PlatformJacob Van Vloten, Seungmi Yoo, Gurleen Sandhu, et al.
Research Square|December 4, 2023
Chimerization of the Anti-Viral CD8<sup>+</sup> T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapyRichard Vile, Mason Webb, Jacob van Vloten, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2025
The progressively exhausted T cell response to a poorly immunogenic model of HCC can be partially rescued by immune checkpoint blockade and is heavily suppressed by T cell responses to oncolytic virotherapyThanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, et al.
Nature Communications|June 27, 2024
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell responseMason J Webb, Thanich Sangsuwannukul, Jacob van Vloten, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.
Pageof 1